We are live on ! Find out more
VBIO

Valion Bio
VBIO

5 hedge funds and large institutions have $43.4K invested in Valion Bio in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more funds holding

Funds holding: 3 → 5 (+2)

45% more capital invested

Capital invested by funds: $30K → $43.4K (+$13.4K)

0% more ownership

Funds ownership: 0% → 0% (+0%)

Holders
5
Holders Change
+2
Holders Change %
+66.67%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$33.7K
2
TSS
Two Sigma Securities
New York
+$15.7K
3
Osaic Holdings
Osaic Holdings
Arizona
+$8.98K
4
TRCT
Tower Research Capital (TRC)
New York
+$4.49K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$17K +$33.7K +15 New
Osaic Holdings
2
Osaic Holdings
Arizona
$9K +$8.98K +4 +80%
TSS
3
Two Sigma Securities
New York
$8.05K +$15.7K +7 New
TRCT
4
Tower Research Capital (TRC)
New York
$7K +$4.49K +2 +40%
UBS Group
5
UBS Group
Switzerland
$2.3K – – –
Wells Fargo
6
Wells Fargo
California
$29 – – –
Bank of America
7
Bank of America
North Carolina
$8 – – –

VBIO Hedge Fund Activity: Q4 2022 in Review

5 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Valion Bio (VBIO) for Q4 2022, worth a combined $43.4K — up 45% from $30K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new VBIO positions and 0 closed out — a net gain of 2 holders — while 2 added to existing stakes and 0 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $33.7K.

  • 5 institutional investors held Valion Bio (VBIO) as of Q4 2022, up from 3 in Q3 2022.
  • Funds reported $43.4K of Valion Bio stock for Q4 2022, up 45% quarter-over-quarter.
  • 2 funds opened new Valion Bio positions in Q4 2022 and 0 closed out, a net change of +2 holders.
  • The largest Valion Bio buyer in Q4 2022 was Renaissance Technologies, an estimated $33.7K added.

Based on aggregated 13F filings for Q4 2022.